Physician profile
Michelle Ehrlich
NPI 1134244635
$734,624.39
in general payments reported to CMS, 2019-2025
47 companies · $257K in 2025
The $257K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $17K · 2021: $22K · 2022: $61K · 2023: $149K · 2024: $177K · 2025: $257K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $359K · Consulting Fee: $128K · Travel and Lodging: $73K · Food and Beverage: $24K · Education: $120 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $359,277.03 |
| Consulting Fee | $127,550.59 |
| Travel and Lodging | $73,006.35 |
| Food and Beverage | $23,501.79 |
| Education | $119.99 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $182,846.04 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $122,008.43 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $84,059.67 | 2019-2025 | Aklief, Oracea, Epsolay |
| Pfizer INC. | $82,553.18 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $78,096.97 | 2023-2025 | Zoryve |
| Incyte Corporation | $66,357.08 | 2021-2025 | Opzelura, Opzelura |
| Verrica Pharmaceuticals INC. | $41,737.83 | 2023-2025 | Ycanth |
| Celgene Corporation | $17,811.82 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $16,303.05 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $14,869.64 | 2022-2024 | Vtama |
| Kowa Pharmaceuticals America, INC. | $7,689.51 | 2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,027.65 | 2019-2022 | |
| Journey Medical Corporation | $2,104.27 | 2021-2025 | |
| Abbvie INC. | $2,046.81 | 2019-2025 | |
| Botanix Sb INC | $1,632.48 | 2025 | Sofdra |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $1,524.96 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Janssen Biotech, INC. | $1,061.66 | 2021-2025 | Tremfya, Remicade, Simponi Aria |
| Ucb, INC. | $1,056.60 | 2019-2025 | Cimzia, Bimzelx |
| Mayne Pharma Commercial LLC | $999.71 | 2019-2025 | |
| Almirall LLC | $634.55 | 2019-2025 | Klisyri |
| Genzyme Corporation | $607.91 | 2019-2023 | |
| Promius Pharma LLC | $500.00 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $457.77 | 2020-2025 | Neo-Synalar, Clindacin Etz |
| Leo Pharma As | $410.83 | 2025 | Adbry |
| Lilly USA, LLC | $217.80 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $215.04 | 2025 | Vtama |
| Revance Therapeutics, INC. | $201.83 | 2024-2025 | Daxi, Daxxify |
| Musculoskeletal Transplant Foundation INC. | $195.29 | 2022 | |
| Alfasigma USA, INC. | $183.06 | 2021-2022 | |
| Merz North America, INC. | $175.84 | 2019-2023 | Xeomin |
| Regeneron Healthcare Solutions, INC. | $170.30 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $147.13 | 2022-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $138.88 | 2019-2023 | |
| Epi Health, LLC | $131.25 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $96.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.30 | 2024 | Spevigo |
| Prugen, INC. Pharmaceuticals | $47.37 | 2019 | |
| Aclaris Therapeutics, INC. | $46.61 | 2019 | |
| Glenmark Therapeutics INC. | $43.00 | 2019 | |
| Mission Pharmacal Company | $39.58 | 2019 | |
| Organogenesis INC. | $38.27 | 2025 | Cygnus Dual |
| Boston Scientific Corporation | $25.22 | 2023 | Wavewriter Alpha Prime 16 |
| Exeltis, USA INC. | $20.06 | 2024 | Slynd |
| Ani Pharmaceuticals, INC. | $17.25 | 2025 | Veregen |
| Sandoz INC. | $13.50 | 2019 | |
| Dermira, INC. | $11.12 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ehrlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.